Larimar Therapeutics, Inc. Share Price

Larimar Therapeutics, Inc. Share Price

NASDAQ: LRMR | Micro Cap
$2.47
-$0.22 (-8.18%) Last updated on 31 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Larimar Therapeutics, Inc. Stock Performance

Open
$2.63
Prev. Close
$2.69
Circuit Range
N/A
Day Range
$2.42 - $2.65
Year Range
$1.92 - $6.42
Volume
58,975
Average Traded
$2.50

Larimar Therapeutics, Inc. Share Price Today

As of 31 October 2026, Larimar Therapeutics, Inc.'s share price is $2.47. The stock opened at $2.63, compared to its previous close of $2.69. During today's trading session, Larimar Therapeutics, Inc.'s share price traded between $2.42 and $2.65, with an average price of $2.54. Over the past 52 weeks, the stock has recorded a high of $6.42 and a low of $1.92. In terms of performance, Larimar Therapeutics, Inc.'s share price has declined by 39.15% over the last six months and is down 36.67% on a year-on-year basis.

Larimar Therapeutics, Inc. Share Price Chart

Line chart of the Larimar Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 2.42 to 2.65, ending at 2.47.
$2.42$2.65
L
Show Current Price
H

Larimar Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$617500.00
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.66
Revenue (TTM)
$0.00
Return On Equity (TTM)
-135.50%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
31.29%

Larimar Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$47.71-$62.50-$29.61-$32.78
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-31.00%52.62%-10.71%

Larimar Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$35.36-$36.95-$80.60-$165.67
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-4.50%-118.13%-105.55%

About Larimar Therapeutics, Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Larimar Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$3.17
$2.46
-23.28%
Sep 2026
$3.80
$3.20
-20.79%
Aug 2026
$3.81
$4.04
+5.62%
Jul 2026
$3.07
$3.83
+25.82%
Jun 2026
$3.45
$3.04
-12.77%
May 2026
$4.03
$3.48
-14.14%
Apr 2026
$4.62
$4.06
-9.80%
Mar 2026
$5.00
$4.50
-15.25%
Feb 2026
$3.48
$5.31
+50.42%
Jan 2026
$3.71
$3.53
-7.47%
Dec 2025
$3.41
$3.81
+7.46%
Nov 2025
$3.95
$3.55
-8.97%

LRMR Share Price FAQs